Oncologic outcomes of stage IIIA colon cancer for different chemotherapeutic regimensopen access
- Authors
- Lee Y.S.[Lee Y.S.]; Kim H.C.[Kim H.C.]; Jung K.O.[Jung K.O.]; Cho Y.B.[Cho Y.B.]; Yun S.H.[Yun S.H.]; Lee W.Y.[Lee W.Y.]; Chun H.-K.[Chun H.-K.]
- Issue Date
- 2012
- Keywords
- Chemotherapeutic agent; Colon neoplasm; Prognosis; Stage IIIA
- Citation
- Journal of the Korean Society of Coloproctology, v.28, no.5, pp.259 - 264
- Indexed
- SCOPUS
- Journal Title
- Journal of the Korean Society of Coloproctology
- Volume
- 28
- Number
- 5
- Start Page
- 259
- End Page
- 264
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/67681
- DOI
- 10.3393/jksc.2012.28.5.259
- ISSN
- 2093-7822
- Abstract
- Purpose: Adjuvant chemotherapy is currently recommended for Stage IIIA colon cancers. This study aimed to elucidate the oncologic outcomes of Stage IIIA colon cancer according to the chemotherapeutic regimen based on a retrospective review. Methods: From 1995 to 2008, Stage IIIA colon cancer patients were identified from a prospectively maintained database at a single institution. Exclusion criteria were as follows: rectal cancer, another malignancy other than colon cancer, no adjuvant chemotherapy and unknown chemotherapeutic regimen. One hundred thirty-one patients were enrolled in the study, and the clinicopathologic and the oncologic characteristics were analyzed. The number of males was 72, and the number of females was 59; the mean age was 59.5 years (range, 25 to 76 years), and the median follow-up period was 33 months (range, 2 to 127 months). Results: Of the 131 patients, fluorouracil/leucovorin (FL)/capecitabine chemotherapy was performed in 109 patients, and FOLFOX chemotherapy was performed in 22 patients. When the patients who received FL/capecitabine chemotherapy and the patients who received FOLFOX chemotherapy were compared, there was no significant difference in the clinicopathologic factors between the two groups. The 5-year overall survival and the 5-year disease-free survival were 97.2% and 94.5% in the FL/capecitabine patient group and 95.5% and 90.9% in the FOLFOX patient group, respectively, and no statistically significant differences were noted between the two groups. Conclusion: Stage IIIA colon cancer showed good oncologic outcomes, and the chemotherapeutic regimen did not seem to affect the oncologic outcome. © 2012 The Korean Society of Coloproctology.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.